沙库巴曲缬沙坦联合冻干重组人脑利钠肽治疗心力衰竭的疗效及对血浆BNP、NT-proBNP水平的影响

Efficacy of sacubitril valsartan combined with lyophilized recombinant human brain natriuretic peptide in the treatment of heart failure and its effect on plasma BNP and NT-proBNP levels

目的探究沙库巴曲缬沙坦联合冻干重组人脑利钠肽治疗心力衰竭的疗效及对血浆脑利钠肽(BNP)、N端脑纳肽原(NT-proBNP)水平的影响。方法回顾性分析2020年1月到2022年6月池州市人民医院收治的62例CHF患者资料,根据其治疗方案的不同将其分为对照组和观察组,各31例。对照组采用沙库巴曲缬沙坦治疗,观察组采用沙库巴曲缬沙坦联合冻干重组人脑利钠肽治疗。比较2组临床疗效、心功能、血浆BNP、NT-proBNP水平及不良反应情况。结果观察组总有效率为96.77%,明显高于对照组(74.19%),差异有统计学意义(P<0.05)。治疗后,2组心率均较治疗前降低,每搏量、左室射血分数(LVEF)均较治疗前升高,且观察组心率低于对照组,每搏量、LVEF高于对照组,差异均有统计学意义(P<0.05)。治疗后,2组BNP、NT-proBNP水平均较治疗前降低,且观察组BNP、NT-proBNP水平低于对照组,差异均有统计学意义(P<0.05)。2组低血压、肾功能损伤、高钾血症等不良反应发生率比较,差异均无统计学意义(P>0.05);观察组再入院率为6.45%,低于对照组(25.80%),差异有统计学意义(P<0.05)。结论沙库巴曲缬沙坦联合冻干重组人脑利钠肽治疗能有效改善心力衰竭患者心功能,降低血浆BNP、NT-proBNP水平,提高临床疗效。

Objective To explore the efficacy of sacubitril valsartan combined with lyophilized recombinant human brain natriuretic peptide in the treatment of heart failure and its effect on plasma brain natriuretic peptide(BNP)and N-terminal pro brain natriuretic peptide(NT-proBNP)levels.Methods A total of 62 patients with chronic heart failure admitted to our hospital from from January 2020 to June 2022 were selected and divided into observation group and control group with 31 cases each according to the different treatment options.The control group received conventional treatment,and the observation group took sacubitril valsartan combined with lyophilized recombinant human brain natriuretic peptide plus conventional treatment.Clinical efficacy,cardiac function,plasma BNP,NT-proBNP levels and adverse reactions between the two groups were compared.Results The total effective rate of observation group and control group were 96.77%and 74.19%,and the total effective rate of observation group was significantly higher(P<0.05).After treatment,HR decreased,stroke volume and left ventricular ejection fraction(LVEF)increased in both groups,and the range of change was greater in the observation group(P<0.05).There was no difference in BNP and NT-probNP levels between the two groups before treatment(P>0.05).After treatment,the two serum indexes showed a downward trend,and the decrease was greater in the observation group(t=19.402,16.321,P<0.05).There was no significant difference in the incidence of adverse reactions such as hypotension,renal damage,hyperkalemia,etc.between the two groups(P>0.05).The readmission rate of the observation group was lower than that of the control group(6.45%vs.25.80%,P<0.05).Conclusion The treatment of sacubitril valsartan combined with lyophilized recombinant human brain natriuretic peptide can effectively improve the heart function,reduce plasma BNP and NT-proBNP levels,and improve clinical efficacy in patients with heart failure.